High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
CSF cell counts
JCPyV
JCV index
Multiple sclerosis
cerebrospinal fluid
clinical activity
natalizumab
progressive multifocal leukoencephalopathy
tissue-resident memory cells
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
6
11
2020
medline:
25
2
2023
entrez:
5
11
2020
Statut:
ppublish
Résumé
Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration. Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk. Cerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiological activity, current steroid or natalizumab treatment, as well as anti-JCPyV serology on CSF cell subset counts. While clinical/radiological activity was associated with increased CD4, natural killer (NK), B and plasma cell counts, natalizumab therapy reduced all subpopulations except monocytes. With and without natalizumab therapy, patients with high anti-JCPyV serum titers presented with increased CSF T-cell counts compared to patients with low anti-JCPyV serum titers. In contrast, PML patients assessed before ( High anti-JCPyV indices, which could be indicative of increased viral activity, are associated with elevated immune cell recruitment to the CNS. Its excessive impairment in conjunction with viral activity could predispose for PML development.
Sections du résumé
BACKGROUND
Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration.
OBJECTIVE
Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk.
METHODS
Cerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiological activity, current steroid or natalizumab treatment, as well as anti-JCPyV serology on CSF cell subset counts.
RESULTS
While clinical/radiological activity was associated with increased CD4, natural killer (NK), B and plasma cell counts, natalizumab therapy reduced all subpopulations except monocytes. With and without natalizumab therapy, patients with high anti-JCPyV serum titers presented with increased CSF T-cell counts compared to patients with low anti-JCPyV serum titers. In contrast, PML patients assessed before (
CONCLUSION
High anti-JCPyV indices, which could be indicative of increased viral activity, are associated with elevated immune cell recruitment to the CNS. Its excessive impairment in conjunction with viral activity could predispose for PML development.
Identifiants
pubmed: 33150829
doi: 10.1177/1352458520970103
pmc: PMC8414828
doi:
Substances chimiques
Natalizumab
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1491-1496Références
Brain. 2018 Jul 1;141(7):2066-2082
pubmed: 29873694
Ann Neurol. 2015 Mar;77(3):447-57
pubmed: 25581547
J Clin Virol. 2008 Oct;43(2):184-9
pubmed: 18676176
N Engl J Med. 2006 Mar 2;354(9):911-23
pubmed: 16510745
Nat Commun. 2018 Nov 2;9(1):4593
pubmed: 30389931
Ann Neurol. 2006 May;59(5):743-7
pubmed: 16634029
Neurol Neuroimmunol Neuroinflamm. 2019 Sep 25;6(6):
pubmed: 31554671
J Exp Med. 2016 Jul 25;213(8):1571-87
pubmed: 27377586
Mult Scler. 2018 Apr;24(5):563-573
pubmed: 28847222
Sci Immunol. 2018 Jun 1;3(24):
pubmed: 29858286
Ann Neurol. 2014 Dec;76(6):802-12
pubmed: 25273271
J Clin Invest. 2005 Jan;115(1):187-94
pubmed: 15630459
Sci Transl Med. 2019 Jun 26;11(498):
pubmed: 31243152
Immunity. 2014 Oct 16;41(4):633-45
pubmed: 25308332
Arch Neurol. 2006 Oct;63(10):1383-7
pubmed: 17030653
Brain. 2019 Nov 1;142(11):3411-3427
pubmed: 31563951
J Exp Med. 2019 May 6;216(5):1214-1229
pubmed: 30923043
N Engl J Med. 2003 Jan 2;348(1):24-32
pubmed: 12510039
Nat Immunol. 2020 Aug;21(8):938-949
pubmed: 32572242
Neurology. 2019 Oct 8;93(15):e1452-e1462
pubmed: 31515290
J Exp Med. 2014 Aug 25;211(9):1833-46
pubmed: 25135296
Neurology. 2017 Mar 21;88(12):1197-1205
pubmed: 28228564
Gastroenterology. 2000 Nov;119(5):1228-35
pubmed: 11054380
Neurology. 2013 Sep 3;81(10):865-71
pubmed: 23925765
PLoS Pathog. 2018 Oct 29;14(10):e1007365
pubmed: 30372487